<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
______________
Date of Report (Date of earliest event reported): December 20, 2000
CuraGen Corporation
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C> <C>
Delaware 0-23223 06-1331400
------------------ --------------------- ---------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
</TABLE>
555 Long Wharf Drive, 11th FLOOR
New Haven, Connecticut 06511
------------------------------------
(Address of principal executive offices) (ZipCode)
Registrant's telephone number, including area code: (203) 401-3330
<PAGE>
ITEM 9. REGULATION FD DISCLOSURE.
On December 20, 2000, the Registrant and the Monsanto Company entered into an
early stage collaboration to apply the Registrant's functional genomic
technologies to discover key genes involved in the growth of crops with improved
quality traits. Specifically, scientists will apply the Registrant's integrated
genomic technologies to measure gene expression in various strains of corn in
order to identify select genes that naturally improve output traits and enhance
the development of corn crops with higher nutritional value.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CURAGEN CORPORATION
(Registrant)
Date: December 20, 2000 By: /s/ David Wurzer
-----------------
Executive Vice President and
Chief Financial Officer
3
